The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of ridaforolimus (MK-8669) in pediatric patients with advanced solid tumors.
Andrew DJ Pearson
No relevant relationships to disclose
Sara Michele Federico
No relevant relationships to disclose
Isabelle Aerts
No relevant relationships to disclose
Darren R Hargrave
No relevant relationships to disclose
Steven G. DuBois
Research Funding - Merck
Robert Iannone
Employment or Leadership Position - Merck
Stock Ownership - Merck
Other Remuneration - Merck
Ryan Geschwindt
Employment or Leadership Position - Merck Sharp & Dohme
Stock Ownership - Merck
Ruixue Wang
No relevant relationships to disclose
Tanya M. Trippett
No relevant relationships to disclose
Birgit Geoerger
No relevant relationships to disclose